CAPR - CAPRICOR THERAPEUTICS, INC.

QQQ $ 449.78 $ 0.86 (0.19 %)

DIA $ 397.71 $ -0.17 (-0.04 %)

SPY $ 527.13 $ 1.21 (0.23 %)

TLT $ 91.84 $ 0.00 (0 %)

GLD $ 219.22 $ -0.02 (-0.01 %)

Previous Close

$ 5.2

Open

$ 5.34

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 5.24 - $ 5.42

52 Week Range

$ 2.68 - $ 8.22

Volume

667,284

Average Volume

Market Cap

163.04M

Beta (5Y Monthly)

$ 0.74

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-11-2024	12-31-2023	10-K
3	11-14-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-12-2023	03-31-2023	10-Q
6	03-17-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-12-2022	06-30-2022	10-Q
9	05-11-2022	03-31-2022	10-Q
10	03-11-2022	12-31-2021	10-K
11	11-11-2021	09-30-2021	10-Q
12	08-13-2021	06-30-2021	10-Q
13	05-14-2021	03-31-2021	10-Q
14	03-15-2021	12-31-2020	10-K
15	11-13-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-15-2020	03-31-2020	10-Q
18	03-27-2020	12-31-2019	10-K
19	11-08-2019	09-30-2019	10-Q
20	08-08-2019	06-30-2019	10-Q
21	05-14-2019	03-31-2019	10-Q
22	03-29-2019	12-31-2018	10-K
23	11-14-2018	09-30-2018	10-Q
24	08-13-2018	06-30-2018	10-Q
25	05-14-2018	03-31-2018	10-Q
26	03-22-2018	12-31-2017	10-K
27	11-14-2017	09-30-2017	10-Q
28	08-14-2017	06-30-2017	10-Q
29	05-15-2017	03-31-2017	10-Q
30	03-16-2017	12-31-2016	10-K
31	11-14-2016	09-30-2016	10-Q
32	08-15-2016	06-30-2016	10-Q
33	05-13-2016	03-31-2016	10-Q
34	03-30-2016	12-31-2015	10-K
35	11-13-2015	09-30-2015	10-Q
36	08-14-2015	06-30-2015	10-Q
37	05-13-2015	03-31-2015	10-Q
38	03-16-2015	12-31-2014	10-K
39	11-14-2014	09-30-2014	10-Q
40	08-14-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Expert Ratings For Capricor Therapeutics
05/14/2024 19:01:00

Ladenburg Thalmann Maintains Buy on Capric...
05/14/2024 18:23:48

Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price targ...

Cantor Fitzgerald Reiterates Overweight on...
05/14/2024 12:58:47

Cantor Fitzgerald analyst Kristen Kluska reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Overweight and maintains $8 p...

HC Wainwright & Co. Reiterates Buy on Capr...
05/14/2024 11:31:35

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

Capricor Therapeutics Expects Available Ca...
05/13/2024 20:20:40

Capricor Therapeutics Q1 2024 GAAP EPS $(0...
05/13/2024 20:16:14

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate ...

Capricor Therapeutics To Present Exosome P...
05/09/2024 13:39:03

-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentatio...

HC Wainwright & Co. Reiterates Buy on Capr...
04/25/2024 11:25:38

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

Capricor Therapeutics Announces Type-B Mee...
04/24/2024 13:04:01

HC Wainwright & Co. Reiterates Buy on Capr...
03/01/2024 11:51:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40...

Recap: Capricor Therapeutics Q4 Earnings
02/29/2024 21:30:15

Capricor Therapeutics Q4 2023 GAAP EPS $(0...
02/29/2024 21:27:20

Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.020) per share which beat the analyst consensus estimate o...

Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

Capricor Therapeutics's Earnings Outlook
02/28/2024 17:01:57

Capricor Therapeutics Announces Type-B Mee...
02/27/2024 13:32:51

Capricor Therapeutics Announces Manufactur...
02/20/2024 13:34:36

-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024-

Capricor Therapeutics Collabores With Nati...
01/24/2024 14:16:53

-Project NextGen Collaboration will Support Capricor's StealthX™ Exosome Platform and Provide Non-Dilutive Support for Adva...

Capricor Therapeutics Receives First Miles...
01/11/2024 14:07:19

Cantor Fitzgerald Initiates Coverage On Ca...
01/05/2024 15:31:57

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Capricor Therapeutics (NASDAQ:CAPR) with a Overweight rating ...

Capricor Therapeutics Announces Outcome Of...
12/11/2023 14:06:52

--Favorable Interim Futility Analysis Results-- --Successful Completion Triggers First Milestone Payment Under U.S. Agreement w...